Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.59 |
| ▸ | CA1 | P00915 | 9/20 | 0.59 |
| ▸ | CA9 | Q16790 | 9/20 | 0.59 |
| ▸ | CA12 | O43570 | 8/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | SNCA | P37840 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11804202 | 0.87 | SNCA (0.55) | CA2CA1CA9CA12CA14 | |
| SCHEMBL175786 | 0.84 | SNCA (0.67) | CA2CA1CA9CA12CA14 | |
| SCHEMBL250839 | 0.80 | CYP3A4 (0.59) | SNCACYP3A4CYP2C19 | |
| SCHEMBL461801 | 0.79 | SNCA (0.61) | SNCAMEN1KMT2ACYP3A4 | |
| SCHEMBL17386391 | 0.79 | SNCA (0.61) | CA2CA1CA9CA12CA14 | |
| SCHEMBL6502299 | 0.78 | KMT2A (0.78) | CA2CA1CA9CA12CA14 | |
| SCHEMBL7460913 | 0.78 | SNCA (0.47) | CA2CA1CA9CA12CA14 | |
| SCHEMBL175787 | 0.78 | SNCA (0.59) | SNCAMEN1KMT2ACYP3A4 | |
| SCHEMBL5675836 | 0.78 | SNCA (0.59) | CA2CA1CA9CA12CA14 | |
| SCHEMBL31182 | 0.78 | SNCA (0.59) | CA2CA1CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-6723749-B2 | TREATING BACTERIAL INFECTIONS | SMITHKLINE BEECHAM CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20040058988-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2004-03-25 | — | — | US | disclosed |
| EP-1322331-A2 | FATTY ACID SYNTHASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1318803-A1 | FATTY ACID SYNTHASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002009651-A2 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002009688-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058988-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | CA2 2194/4885CA1 2910/4885CA9 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.